Education
About Us
Working with TipRanks
Follow Us
Maze Therapeutics, Inc. (MAZE)
NASDAQ:MAZE
MAZE Stock Chart & Stats
$45.03
--
Market closed
$45.03
--
Day’s Range― - ―
52-Week Range$6.71 - $49.25
Previous CloseN/A
VolumeN/A
Average Volume (3M)422.13K
Market Cap
$2.17B
Enterprise Value$1.99B
Total Cash (Recent Filing)$383.94M
Total Debt (Recent Filing)$24.18M
Price to Earnings (P/E)―
Beta0.99
Next Earnings
Apr 06, 2026EPS Estimate
-0.71Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.66
Shares Outstanding48,119,446
10 Day Avg. Volume616,259
30 Day Avg. Volume422,133
Financial Highlights & Ratios
PEG Ratio-0.13
Price to Book (P/B)3.55
Price to Sales (P/S)4.17
P/FCF Ratio9.34
Enterprise Value/Market Cap0.92
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-3.07K
Enterprise Value/Ebitda-15.78
Forecast
1Y Price Target
$52.00Price Target Upside15.48% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-3.14
Revenue Forecast (FY)$2.00M
Bulls Say, Bears Say
Bulls Say
Market Opportunity And CompetitionAPOL1 is a genetically defined target with no approved therapies and a potentially addressable US population of over 250,000, and limited competing programs create substantial commercial upside if clinical efficacy is established.
Mechanism And DifferentiationAnalysts emphasize MZE829's dual mechanism that inhibits APOL1 pore formation and function and mimics a protective genetic variant, which could deliver higher potency and a meaningful clinical advantage if confirmed by trials.
Pediatric Regulatory PathwayStrong adult biomarker results could support bridging adult efficacy to pediatric labeling, potentially limiting pediatric testing to safety and dosing studies and accelerating access for children while reducing development costs.
Bears Say
Efficacy Uncertainty In Diabetic PatientsKey opinion leaders caution that diabetic kidney disease has multiple drivers, so patients with diabetes may see smaller proteinuria benefits, which could blunt overall treatment impact in a large subgroup.
Limited Trial GeneralizabilityThe Phase 2 update excludes the most severe kidney disease cohort and focuses on lower‑protein diabetic and non‑diabetic groups, which may limit how broadly positive results can be applied across the full patient population.
Uncertain Commercial Impact From Safety‑focused DesignBecause the primary objective of the current trial is safety and tolerability and patient‑level efficacy data remain limited, analysts assign a cautious probability of success and the stock valuation may be sensitive to clinical progress.
Maze Therapeutics, Inc. News
MAZE FAQ
What was Maze Therapeutics, Inc.’s price range in the past 12 months?
Maze Therapeutics, Inc. lowest stock price was $6.71 and its highest was $49.25 in the past 12 months.
What is Maze Therapeutics, Inc.’s market cap?
Maze Therapeutics, Inc.’s market cap is $2.17B.
When is Maze Therapeutics, Inc.’s upcoming earnings report date?
Maze Therapeutics, Inc.’s upcoming earnings report date is Apr 06, 2026 which is in 54 days.
How were Maze Therapeutics, Inc.’s earnings last quarter?
Maze Therapeutics, Inc. released its earnings results on Nov 06, 2025. The company reported -$0.66 earnings per share for the quarter, beating the consensus estimate of -$0.708 by $0.048.
Is Maze Therapeutics, Inc. overvalued?
According to Wall Street analysts Maze Therapeutics, Inc.’s price is currently Undervalued.
Does Maze Therapeutics, Inc. pay dividends?
Maze Therapeutics, Inc. does not currently pay dividends.
What is Maze Therapeutics, Inc.’s EPS estimate?
Maze Therapeutics, Inc.’s EPS estimate is -0.71.
How many shares outstanding does Maze Therapeutics, Inc. have?
Maze Therapeutics, Inc. has 48,119,446 shares outstanding.
What happened to Maze Therapeutics, Inc.’s price movement after its last earnings report?
Maze Therapeutics, Inc. reported an EPS of -$0.66 in its last earnings report, beating expectations of -$0.708. Following the earnings report the stock price went down -3.476%.
Which hedge fund is a major shareholder of Maze Therapeutics, Inc.?
Currently, no hedge funds are holding shares in MAZE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Maze Therapeutics, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$52.00 (15.48% Upside)
$52.00 (15.48% Upside)
Blogger Sentiment
Bullish
MAZE Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 553.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 3.6%
Last 30 Days ▲ 7.2%
Last 30 Days ▲ 7.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
246.38%
12-Months-Change
Fundamentals
Return on Equity
-36.13%
Trailing 12-Months
Asset Growth
119.27%
Trailing 12-Months
Company Description
Maze Therapeutics, Inc.
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States. Its lead programs includes MZE829, an oral small molecule inhibitor of apolipoprotein L1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor of the solute transporter SLC6A19, which is in phase I clinical trial for the treatment of chronic kidney disease. Maze Therapeutics, Inc. was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
MAZE Stock 12 Month Forecast
Average Price Target
$52.00
▲(15.48% Upside)
Technical Analysis
Ownership Overview
12.09% Insiders
4.34% Mutual Funds
0.58% Other Institutional Investors
76.74% Public Companies and
Individual Investors